Salute e Benessere

Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to…

·More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults.1 ·DRD is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe. 2,3 ·There is an urgent need for earlier detection of DRD and novel treatments that work in earlier disease states before vision loss occurs. Ingelheim, Germany and Ann Arbor, MI, USA,...
Nasdaq GlobeNewswire
12/11/2024

2024 Tsingke High-Impact Literature Compilation - Gene Synthesis

Compilation of High-Impact Literature Compilation of High-Impact Literature 1.Title: Enhancing rice panicle branching and grain yield through tissue-specific brassinosteroid inhibitionDOI:10.1126/science.adk8838 Journal:Science Impact Factor:56.9Summary:This study shows that crop yield potential is limited by inherent trade-offs between grain size and number. While brassinosteroids (BRs) promote grain enlargement, their role in regulating grain number has been...
PR Newswire
12/11/2024

deCODE genetics/Amgen: New Study Explores the Role of BMI in Disease Risk

The results showed that for some conditions, such as fatty liver disease, glucose intolerance, and knee replacement, the genetic link to disease disappeared when BMI was taken into account. For other conditions, like type 2 diabetes, heart failure, and stroke, the effects were largely reduced but not entirely explained by BMI. The results showed that for some conditions, such as fatty liver disease, glucose intolerance, and knee replacement, the genetic link to disease disappeared when BMI…
PR Newswire
12/11/2024

Access Accelerated and the World Bank Collaborate via New Technical Partnership…

The Financing Accelerator Network for NCDs aims to address this challenge by supporting governments and local stakeholders in strengthening their NCD response and building more resilient health financing systems, with a focus on advancing universal health coverage and building strong primary healthcare systems – key goals within the 2030 Sustainable Development Goals. The Financing Accelerator Network for NCDs aims to address this challenge by supporting governments and local stakeholders in...
PR Newswire
12/11/2024

EDAN Unveils Latest Innovations for Global Healthcare at MEDICA 2024

Marking 10 years in the blood gas field, EDAN officially reaching audiences with i500 this year, as one of the world's smallest benchtop analyzers with true zero maintenance, delivering over 30 parameters per test. The new Blood Sampler offers safer sampling with size options, ensuring accuracy by reducing ion interference via calcium-balanced heparin-lithium coating. Expanding in IVD, EDAN introduces the H90 Series hematology analyzer, utilizing 3D fluorescence technology for precise RET, DIFF…
PR Newswire
12/11/2024

Tsingke Successfully Showcases Innovations at BIO-Europe 2024

A Hub for Partnerships and Collaboration A Hub for Partnerships and Collaboration Tsingke's booth attracted significant attention, with many attendees eager to explore potential collaborations. Hundreds of Industry professionals from various sectors, including pharmaceutical research, biotechnology, and academia, had deeply engaged with Tsingke's professional team and discovered how its solutions can help researchers accelerate their work and address complex challenges in a variety of...
PR Newswire
12/11/2024

Barts Health Implements Cynerio's Healthcare Cybersecurity Platform

To best serve their community, Barts Health has opted to implement Cynerio's full suite, including Network Detection and Response for Healthcare (NDR-H) technology designed to monitor network traffic and detect and respond to threats. Cynerio's NDR-H sits within the hospital's network and monitors traffic without interfering with traffic flow, identifying unusual traffic, performing analysis, and alerting team members to potential attacks that could impact their ability to provide care. To…
PR Newswire
12/11/2024

MintNeuro Secures £1M Investment to Advance Transformative Semiconductor…

Neurological disorders impact over a billion people globally and pose a significant social and economic burden. Current treatments, especially pharmaceuticals, are often ineffective or fail to provide long-term solutions. With drug development becoming increasingly costly and less productive, many patients are left without effective care options. Neural implants offer a promising alternative, yet traditional technologies remain bulky, power-intensive, and reliant on invasive surgeries that limit…
PR Newswire
12/11/2024

Agenda for Essity's Capital Markets Day Accelerating Profitable Growth

Register for Essity's Capital Markets Day here, November 15, 2024, at the latest. The day will not be livestreamed. Material from parts of the day will be available on Essity's website after the event. Register for Essity's Capital Markets Day here,November 15, 2024, at the latest. The day will not be livestreamed. Material from parts of the day will be available on Essity's website after the event. Agenda - Accelerating profitable growth–Magnus Groth, President and...
PR Newswire
12/11/2024

SciBase decides on a directed issue of approximately SEK 22.5 million and a…

"Our existing owners together with the new participating in the directed issue now secure our financial position. We think it is a statement of strength to be able to bring in new long-term owners in this market climate without a discount to market. We are in an expansive phase with a strong focus on the US market where we see strong growth and high interest among clinics, and where Nevisense has recently been recognized and supported by leading doctors for its ability to significantly…
PR Newswire
12/11/2024

SciBase: Interim report January 1 - September 30, 2024

January - September in figures January - September in figures Important events during the quarter Important events after the end of the period This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET onNovember 12, 2024. This report has been comprehensively reviewed by the Company's auditors...
PR Newswire
12/11/2024

Turacoz Group bridging the gap between global and regional teams in medical…

Sharing the dais with Dr. Almudena Fraga, Director Global CX, Campaigns and Content in Marketing Operations, Lundbeck, Dr. Viraj Rajadhyaksha, Area Medical Director, AstraZeneca and Dr. Maged Saleh, Global BAVENCIO® Peer-to-Peer Marketing Lead, Merck, the panel discussed about the existing gaps between the global and local content creation teams, how these gaps can be better bridged by better collaboration, how the insights collected can be shared across teams to be integrated with the overall…
PR Newswire
12/11/2024

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics…

Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory Board, further strengthening support for the Company's long-term growth strategyNBTXR3 program update from pancreatic cancer study and lung cancer study with MD Anderson expected 4Q 2024 and 1H 2025, respectivelyUpdate on expansion of product portfolio to include disruptive...
Nasdaq GlobeNewswire
12/11/2024

Canton Fair Hosts Industry Trend Forum on Home Furnishing and Market Strategy

The "Home Trends in 2025" report applies the STEPIC framework, covering six dimensions: society, technology, environment, politics, industry and creativity. This comprehensive analysis provides insights into market drivers and areas of innovation. The report paints a blueprint for the future of home living with sustainability, personalization and intelligence at its core, the trends of which not only shape the future direction of product design and interior design, but also have a…
PR Newswire
12/11/2024

ONWARD Medical Schedules Webcast to Provide Q3 2024 Update and Year-to-Date…

Company to provide update on significant milestones and near-term plans, including its recent successful financing and agreements with Ottobock and CEA The webcast will be held on November 26, 2024, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver who will discuss highlights from Q3 2024 and provide a business update.To join the webcast via Zoom, please register using thislink.Participants may also join by phone:+32 2 290 9360 (Belgium)+33 1 7095 0350 (France)...
Nasdaq GlobeNewswire
12/11/2024

World's First Patent Acquired for Animal Supplement "Pinfenon" (S) (R)

(*) According to the Japan Patent Office's survey of global common awareness (Paragraph 1, Article 29, the Trademark Act) (*) According to the Japan Patent Office's survey of global common awareness (Paragraph 1, Article 29, the Trademark Act) Photo1: Patent recently acquired for Supplement Pinfenon (S) (R) series launched in 2004https://cdn.kyodonewsprwire.jp/prwfile/release/M103184/202410238652/_prw_PI1fl_5xfktVk4.jpg Mitral regurgitation, a cardiac disorder frequently observed in...
PR Newswire
12/11/2024

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European…

Saint-Herblain (France), November 12, 2024 –Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe.Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host moderated “fireside chat” presentations to discuss the Company's key value drivers and...
Nasdaq GlobeNewswire
12/11/2024

Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with…

Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive supply agreement with Ali Al Suwaidi Trading Est. (ASTE) for the treatment of patients with Duchenne muscular dystrophy (DMD) with AGAMREE under a Named Patient Program. The agreement enables ASTE, a pioneering healthcare distributor with over four decades of experience in Qatar, to address the high unmet need of DMD patients in the region. As the sole distributor of AGAMREE...
Nasdaq GlobeNewswire
12/11/2024

Perceptive eClinical Launches ClinPhone 5: A Ground-breaking new RTSM Platform…

Developed in partnership with CRScube, a renowned South Korean clinical research technology provider, the purpose-built new cloud native and multi-tenanted platform has been designed to accelerate the set-up and delivery of clinical trials, while also providing agility, adaptability, and scalability. Developed in partnership with CRScube, a renowned South Korean clinical research technology provider, the purpose-built new cloud native and multi-tenanted platform has been designed to…
PR Newswire
12/11/2024

Global D-Dimer Testing Market to Observe Growth at a CAGR of ~5% by 2030 |…

Key Takeaways from the D-Dimer Testing Market Report Key Takeaways from the D-Dimer Testing Market Report To read more about the latest highlights related to the D-dimer testing market, get a snapshot of the key highlights entailed in the Global D-Dimer Testing Market Report D-Dimer Testing Overview D-dimer testing is a blood test used to detect the presence of abnormal blood clotting, often aiding in the diagnosis of conditions related to thrombosis, such as deep vein...
PR Newswire
11/11/2024

NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma…

Key Takeaways from the NK Cell Therapy Pipeline Report Key Takeaways from the NK Cell Therapy Pipeline Report Request a sample and discover the recent advances in the NK cell therapy segment @ NK Cell Therapy Pipeline Report The NK cell therapy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage NK cell therapies, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an...
PR Newswire
11/11/2024

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share,...
Nasdaq GlobeNewswire
11/11/2024

Innocan to Direct Full Focus on Following Positive FDA Engagement and…

Innocan has received FDA support to advance its LPT-CBD platform for human use under the 505(b)(2) abbreviated pathway, offering a quicker route to commercial approval. The FDA has also aligned on Innocan's non-clinical development plan and Phase I clinical study design for the LPT-CBD's Investigational New Drug (IND) filing, moving the Company closer to an accelerated approval process. Furthermore, it is noted that Innocan has made strong progress with the FDA's Center for...
PR Newswire
11/11/2024

Alkermes to Participate in Two Upcoming Investor Conferences

Jefferies London Healthcare ConferenceDate/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET (1:00 p.m. GMT) Jefferies London Healthcare Conference Date/Time: Tuesday, Nov. 19, 2024 at8:00 a.m. ET( 1:00 p.m. GMT ) The live webcasts may be accessed under the Investors tab onwww.alkermes.comand will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has...
PR Newswire
11/11/2024
Altri  Comunicati